Key result
Nearly one-third (33%) of patients undergoing cardiac device placement had advanced chronic kidney disease (stages 3-5) at the time of the procedure.
Why the study?
Patients with CKD frequently require cardiac devices that can compromise vascular access, but data on the prevalence and progression of CKD in patients receiving these devices were needed.
Observational (n=688)
No
Nearly one-third of patients undergoing cardiac device placement have advanced chronic kidney disease, suggesting that leadless or subcutaneous devices should be considered to preserve central veins for future hemodialysis access.
One-third of device recipients have advanced CKD; supports routine eGFR screening but leaves open effects on access and progression.
BACKGROUND: Cardiovascular issues (especially arrhythmia and sudden cardiac death) are one of the most common causes of mortality in patients with chronic kidney disease (CKD). To minimize cardiac mortality, these patients frequently require various cardiac devices, such as pacemakers, loop recorders, and defibrillators which can compromise their vascular access. In this study, we aim to determine the prevalence of CKD in patients undergoing cardiac device placement and their progression of CKD. METHODS: Institutional review board approval was obtained for this study. A total of 688 patients undergoing cardiac device placement were included in this study over a 3-year period at Jersey Shore University Medical Center. Demographic characteristics, comorbidities, base-line renal functions during the procedure, types of cardiac devices, sites of vascular access and follow-up renal function when available were assessed retrospectively. Patients were categorized into CKD stages 1 - 5 based on the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines. The patients who were already on hemodialysis were excluded in this study. RESULTS: The average age of the patient were 73.9 years with male predominance (60%). A total of 227 patients (33%) had estimated glomerular filtration rate (eGFR) < 60 mL/min consistent with the evidence of advanced-stage CKD (stages 3 - 5) at the time of cardiac device placement. The most common types of device placements were new insertion/replacement of atrial and ventricular leads (39.5%), loop recorder implantation (21.1%) and generator changes on an already implanted device (11%). Only 4% (28/688) had a leadless cardiac device placement. The most common access sites were subclavian (47.1%), axillary (32.3%) and femoral (12.2%). CONCLUSIONS: The present study demonstrated that nearly one-third of the patient undergoing cardiac device placement had an advanced degree of renal failure. Because CKD is a progressive disease, many of these patients might require renal replacement therapy in the future. Transvenous devices is not a good choice in this group of patients as they will ultimately require an arteriovenous fistula. Subcutaneous leadless cardiac device insertion might be a better option in patients with advanced CKD.
No takes yet. Share an insight, caveat, or question.
Hossain et al. (2020) conducted an observational in Cardiac device placement (n=688). Cardiac device placement was evaluated on Prevalence of advanced-stage CKD (stages 3-5). Nearly one-third (33%) of patients undergoing cardiac device placement had advanced chronic kidney disease (stages 3-5) at the time of the procedure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: